CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
CervoMed management will speak on a neuroscience panel and host investor meetings at the ROTH Healthcare Opportunities Conference.
Rhea-AI Summary
CervoMed (CRVO) will participate in the 5th Annual ROTH Healthcare Opportunities Conference in New York, NY, on Tuesday, September 29, 2026.
Company management is scheduled to join a panel titled “Frontiers in Neuroscience” from 10:00 AM to 10:50 AM ET and hold one-on-one meetings. The panel will not be webcast live, but a recording will be made available after the conference. Meeting requests and additional conference details can be obtained through a Roth institutional representative or by emailing cervomed@argotpartners.com.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 5th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Tuesday, September 29, 2026.
Panel Details
Title: "Frontiers in Neuroscience"
Date: Tuesday, September 29, 2026
Time: 10:00 AM – 10:50 AM ET
This panel will not be webcast. A recording of the panel will be available following the conference. To request a meeting or for more details about the Conference, please reach out to your institutional representative at Roth or contact cervomed@argotpartners.com.
About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology, and the Company announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.
Contacts:
Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431
Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is the topic and schedule of CervoMed's panel at the ROTH conference?
CervoMed management will participate in a panel titled “Frontiers in Neuroscience” at the 5th Annual ROTH Healthcare Opportunities Conference on Tuesday, September 29, 2026, from 10:00 AM to 10:50 AM ET in New York, NY.
Will CervoMed's panel at the ROTH conference be available online?
The panel will not be webcast live. A recording of the panel will be available following the conference.
How can investors request a one-on-one meeting with CervoMed at the conference?
To request a meeting or obtain more details about the conference, interested parties can contact their institutional representative at Roth or email cervomed@argotpartners.com.